Literature DB >> 26078018

Non-contrast cardiac resynchronization therapy implantation is feasible in case of renal insufficiency.

Sok-Sithikun Bun1, Decebal Gabriel Latcu2, Abdelkarim Errahmouni2, Nadir Saoudi2.   

Abstract

PURPOSE: Renal insufficiency (RI) is frequent in patients eligible for cardiac resynchronization therapy (CRT) and may be worsened by the use of contrast agents. We sought to determine the feasibility of CRT implantation without contrast injection in patients with contraindication to iodine.
METHODS: Patients eligible for CRT and presenting with RI were prospectively included (non-contrast NC group). A contemporary control group (CG) of CRT patients with contrast injection was used for comparison. An over-the-wire coronary sinus (CS) lead with an angled distal tip was selected for this "blind harpooning" technique.
RESULTS: Seventeen patients in the NC group were included (78 ± 7 years). Serum creatinine was 208 ± 86 μmol/L (glomerular filtration rate 33 ± 15 mL/min/1.73 m(2)). CG included 25 patients (70 ± 7 years, serum creatinine 85 ± 21 μmol/L). CRT implantation was successful in 16/17 patients (94.1 %) without contrast injection. The mean procedure and fluoroscopy times were similar in the two groups: 146 ± 29 in the NC group versus 153 ± 25 min (p = 0.57) and 25 ± 12 in the NC group versus 23 ± 16 min (p = 0.7) respectively. The mean CS lead implantation time was 36 ± 19 (NC group) versus 39 ± 15 min (p = 0.64). No major procedure-related complications were observed in both groups.
CONCLUSION: CRT implantation is feasible in the majority of the cases (94.1 %) without contrast injection and without lengthening the procedure time in patients with RI.

Entities:  

Keywords:  CRT; Non-contrast; Renal insufficiency

Mesh:

Substances:

Year:  2015        PMID: 26078018     DOI: 10.1007/s10840-015-0027-z

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  16 in total

1.  2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA).

Authors:  Michele Brignole; Angelo Auricchio; Gonzalo Baron-Esquivias; Pierre Bordachar; Giuseppe Boriani; Ole-A Breithardt; John Cleland; Jean-Claude Deharo; Victoria Delgado; Perry M Elliott; Bulent Gorenek; Carsten W Israel; Christophe Leclercq; Cecilia Linde; Lluís Mont; Luigi Padeletti; Richard Sutton; Panos E Vardas
Journal:  Europace       Date:  2013-06-24       Impact factor: 5.214

2.  Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis.

Authors:  Ramesh de Silva; Nikolay P Nikitin; Klaus K A Witte; Alan S Rigby; Kevin Goode; Sunil Bhandari; Andrew L Clark; John G F Cleland
Journal:  Eur Heart J       Date:  2005-12-19       Impact factor: 29.983

3.  Prognostic value of renal function in patients with cardiac resynchronization therapy.

Authors:  Jeffrey W H Fung; Cheuk C Szeto; Joseph Y S Chan; Qing Zhang; Hamish C K Chan; Gabriel W K Yip; Cheuk M Yu
Journal:  Int J Cardiol       Date:  2006-12-15       Impact factor: 4.164

4.  Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis.

Authors:  John G F Cleland; Valentina Carubelli; Teresa Castiello; Ashraf Yassin; Pierpaolo Pellicori; Renjith Antony
Journal:  Heart Fail Rev       Date:  2012-03       Impact factor: 4.214

5.  Incidence of contrast-induced acute kidney injury associated with diagnostic or interventional coronary angiography.

Authors:  Santo Morabito; Valentina Pistolesi; Giulia Benedetti; Angelo Di Roma; Riccardo Colantonio; Massimo Mancone; Gennaro Sardella; Loredana Cibelli; Mariacarmela Ambrosino; Francesca Polistena; Alessandro Pierucci
Journal:  J Nephrol       Date:  2012 Nov-Dec       Impact factor: 3.902

6.  Investigation of coronary venous anatomy by retrograde venography in patients with malignant ventricular tachycardia.

Authors:  E Meisel; D Pfeiffer; L Engelmann; J Tebbenjohanns; B Schubert; S Hahn; E Fleck; C Butter
Journal:  Circulation       Date:  2001-07-24       Impact factor: 29.690

7.  Impact of renal insufficiency on long-term clinical outcome in patients with heart failure treated by cardiac resynchronization therapy.

Authors:  Junya Hosoda; Toshiyuki Ishikawa; Kohei Matsushita; Katsumi Matsumoto; Yuichiro Kimura; Mihoko Miyamoto; Hideyuki Ogawa; Takeshi Takamura; Teruyasu Sugano; Tomoaki Ishigami; Kazuaki Uchino; Kazuo Kimura; Satoshi Umemura
Journal:  J Cardiol       Date:  2012-07-02       Impact factor: 3.159

8.  An 8-year single-centre experience of cardiac resynchronisation therapy: procedural success, early and late complications, and left ventricular lead performance.

Authors:  Syed Y Ahsan; Bunny Saberwal; Pier D Lambiase; Sanjay Chaubey; Oliver R Segal; Aerokondal B Gopalamurugan; James McCready; Dominic P Rogers; Martin D Lowe; Anthony W C Chow
Journal:  Europace       Date:  2013-01-12       Impact factor: 5.214

9.  Chronic kidney disease and cardiac remodelling in patients with mild heart failure: results from the REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) study.

Authors:  Jehu Mathew; Ronit Katz; Martin St John Sutton; Sanjay Dixit; Edward P Gerstenfeld; Stefano Ghio; Michael R Gold; Cecilia Linde; Michael G Shlipak; Rajat Deo
Journal:  Eur J Heart Fail       Date:  2012-09-06       Impact factor: 15.534

10.  Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterized by dyssynchrony: a pre-defined analysis from the CARE-HF trial.

Authors:  Matthew Richardson; Nick Freemantle; Melanie J Calvert; John G F Cleland; Luigi Tavazzi
Journal:  Eur Heart J       Date:  2007-05-31       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.